What is Ozempic?
Also: semaglutide
Semaglutide branded for type 2 diabetes. The drug behind the celebrity weight-loss headlines.
Ozempic is the brand name for semaglutide, a once-weekly injectable GLP-1 receptor agonist manufactured by Novo Nordisk and FDA-approved for type 2 diabetes in 2017. It is not FDA-approved for weight loss — Wegovy is the same drug at a higher dose marketed for that. Most of the celebrity "Ozempic" coverage in 2026 is technically off-label or compounded prescribing.
Quick definition
Ozempic doses for diabetes: 0.25 mg starter, titrating up to 0.5, 1.0, or 2.0 mg per week. Wegovy doses: titrating up to 2.4 mg per week. Same active ingredient, different label.
How it actually works
Semaglutide mimics natural GLP-1 with a much longer half-life — about a week. It slows stomach emptying, suppresses appetite signaling in the hypothalamus, and improves glucose-dependent insulin secretion. Patients typically lose 1 to 2 percent of bodyweight per month at therapeutic dose.
The SUSTAIN-6 cardiovascular outcomes trial (Marso et al., 2016, NEJM) found semaglutide reduced major cardiovascular events by 26 percent in diabetic patients over two years — an unusual win for a glucose-lowering drug. The STEP weight-management trials extended that body of evidence to non-diabetic obese patients.
The reason Ozempic became culturally famous (not Wegovy, the on-label weight-loss version) is supply, marketing, and timing. Wegovy launched in mid-2021 and immediately went into shortage. Doctors began prescribing Ozempic off-label for weight loss to fill the gap, and "Ozempic" stuck in the popular vocabulary.
Why it matters for weight loss
If a celebrity has dropped 30+ pounds in 2026 without acknowledging surgery, GLP-1s are statistically the most likely answer. Most won't confirm. Marin's celebrity-desk pieces (see our celebrity coverage) treat unconfirmed Ozempic speculation as exactly that — speculation.
Common misconceptions
The biggest myth: Ozempic "melts fat." It doesn't. It suppresses appetite so dramatically that intake drops 30 to 40 percent, producing fat loss through a normal deficit. Same mechanism as every diet ever — just powered by a drug instead of willpower.
The second myth: it's a free ride. Side effects (nausea, constipation, gallbladder problems) are common, especially during dose titration. Roughly 5 to 10 percent of users discontinue due to GI side effects.
Related terms
- GLP-1 Agonist · Glucagon-Like Peptide-1 Receptor Agonist A drug class that mimics a gut hormone, slowing digestion and dampening appetite.
- Wegovy Semaglutide at the FDA-approved weight-loss dose. Same drug as Ozempic, different branding.
- Mounjaro Tirzepatide — a dual GIP/GLP-1 agonist. Larger weight-loss numbers than semaglutide in head-to-head data.
- Metformin A first-line type 2 diabetes drug. Off-label for weight loss — modest, not a fat melter.
- Insulin Sensitivity How responsive your cells are to insulin. High sensitivity = good. Low sensitivity (resistance) = trouble.
Read next on Real Easy Diet
Sources
-
[01]
Semaglutide — STEP trial in NEJM New England Journal of Medicine
- [02]
-
[03]
Semaglutide drug info — Mayo Clinic Mayo Clinic
A printable plan that refuses to count almonds.
Four-week schedule. Grocery list. Swap rules. No "fat-burning loophole." No app to download. You print it, you stick it on the fridge, you eat real food.
- 4-week schedule
- Grocery PDF
- Swap rules
- No app, no fees